Neurotune Overview
- Year Founded
-
2005
- Status
-
Private
- Employees
-
5
- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Neurotune General Information
Description
Operator of a drug discovery and biotech company intended to develop medications for neuromuscular diseases. The company provides C-terminal fragments of agrin and enzyme-linked immunosorbent assay and diagnostic assays for the detection of the C-terminal fragment of an agrin biomarker for renal disease detection, enabling patients to have access to medications for neuromuscular diseases.
Contact Information
Website
www.neurotune.comCorporate Office
- Wagistrasse 27 a
- 8952 Schlieren
- Switzerland
Corporate Office
- Wagistrasse 27 a
- 8952 Schlieren
- Switzerland
Neurotune Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 01-May-2023 | Completed | Startup | |||
| 7. Angel (individual) | 29-Jul-2008 | Completed | Startup | |||
| 6. Seed Round | 13-Apr-2007 | Completed | Startup | |||
| 5. Seed Round | 17-Jul-2006 | Completed | Startup | |||
| 4. Grant | 03-Jul-2006 | Completed | Startup | |||
| 3. Seed Round | 23-Dec-2005 | Completed | Startup | |||
| 2. Angel (individual) | Completed | Startup | ||||
| 1. University Spin-Out | 01-Jan-2005 | Completed | Startup |
Neurotune Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary |
Neurotune Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Neurotune Patents
Neurotune Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2015010217-A1 | Dimiracetam in the treatment of depression | Inactive | 24-Jul-2013 | ||
| WO-2013124072-A1 | Immunoassay for the detection of c-terminal fragments of agrin containing the 22kda c-terminal fragment (caf) of agrin | Inactive | 25-Feb-2012 | ||
| EP-2631657-A1 | Immunoassay for the detection of the 22kda c-terminal fragment (caf) of agrin | Inactive | 25-Feb-2012 | ||
| EP-2817634-A1 | Method for the determination of renal function | Inactive | 25-Feb-2012 | ||
| US-20150031057-A1 | Method for the determination of renal function | Inactive | 25-Feb-2012 | G01N33/6893 |
Neurotune Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Neurotune Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| University of Zürich | University |
Neurotune FAQs
-
When was Neurotune founded?
Neurotune was founded in 2005.
-
Where is Neurotune headquartered?
Neurotune is headquartered in Schlieren, Switzerland.
-
What is the size of Neurotune?
Neurotune has 5 total employees.
-
What industry is Neurotune in?
Neurotune’s primary industry is Drug Discovery.
-
Is Neurotune a private or public company?
Neurotune is a Private company.
-
What is Neurotune’s current revenue?
The current revenue for Neurotune is .
-
How much funding has Neurotune raised over time?
Neurotune has raised $9.8M.
-
Who are Neurotune’s investors?
University of Zürich has invested in Neurotune.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
